Corbus Pharmaceuticals Holdings (CRBP) Non-Current Debt (2013 - 2024)

Corbus Pharmaceuticals Holdings' Non-Current Debt history runs 6 years deep, the most recent figure standing at $10.7 million for Q2 2024.

• In Q2 2024, Non-Current Debt fell 5.08% year-over-year to $10.7 million; the TTM figure through Jun 2024 stood at $10.7 million (down 5.08% YoY), while the FY2023 annual figure was $15.9 million, changed 0.48% from the prior year.
• Non-Current Debt was $10.7 million for Q2 2024 at Corbus Pharmaceuticals Holdings, down from $15.9 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $18.6 million in Q3 2021 to a low of $9.4 million in Q3 2022.
• Historically, Non-Current Debt has averaged $14.9 million across 5 years, with a median of $15.8 million in 2021.
• The sharpest annual moves came in 2021 and 2022: Non-Current Debt advanced 3.89% in 2021, then tumbled 49.4% in 2022.
• A 5-year view of Non-Current Debt shows it stood at $18.0 million in 2020, then dropped by 13.27% to $15.6 million in 2021, then gained by 2.23% to $16.0 million in 2022, then declined by 0.48% to $15.9 million in 2023, then sank by 32.46% to $10.7 million in 2024.
• The last three Non-Current Debt figures came in at $10.7 million (Q2 2024), $15.9 million (Q4 2023), and $11.3 million (Q2 2023), per Business Quant data.